Ultrasonic blasting nanobubble targeting hepatic stellate cells as well as preparation method and application of ultrasonic blasting nanobubble

By coating anti-hepatic fibrotic drugs and perfluoroalkanes in ultrasonic burst nanobubbles of liver stellate cells, and combining liver stellate cells to target polypeptides, the precise release of drugs at the liver fibrosis site was achieved using ultrasound stimulation, which solved the problem of The poor targeting of existing drugs in the treatment of liver fibrosis has significantly improved the therapeutic effect and reduced side effects.

CN118949057AInactive Publication Date: 2024-11-15GUANGDONG GENERAL HOSPITAL
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202410869921.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-01
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing drugs lack targeting in the treatment of liver fibrosis, resulting in low drug utilization, large side effects, and difficulty in effectively accumulating in liver target organs and cells, thereby affecting the therapeutic effect.

Method used

An ultrasonic burst nanovesicle targeting hepatic stellate cells was designed to stimulate by coating anti-hepatic fibrotic drugs and perfluoroalkanes in nanovesicles, and combining hepatic stellate cell-targeting polypeptides, using ultrasonic irradiation. Perfluoroalkanes undergo phase change to achieve accurate release of drugs at the liver fibrosis site.

Benefits of technology

It significantly increases the concentration of the drug in the liver fibrosis site, effectively inhibits the activation of HSCs, significantly improves the effect of treating liver fibrosis, reduces the side effects of the drug on the system, and realizes the precise treatment of liver fibrosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949057A_ABST
    Figure CN118949057A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biomedical nano-materials, and particularly relates to a hepatic stellate cell targeted ultrasonic blasting nano-bubble and a preparation method and application thereof, the hepatic stellate cell targeted ultrasonic blasting nano-bubble comprises a nano-vesicle, the nano-vesicle comprises a wall material, and an anti-hepatic fibrosis drug and perfluoroalkane coated in the wall material; the hepatic stellate cell targeting polypeptide is connected to the surface of the nano vesicle, the hepatic stellate cell targeting ultrasonic blasting nano vesicle has high targeting performance on the hepatic fibrosis part, the side effect is remarkably reduced, the treatment effect of hepatic fibrosis is improved, and accurate treatment of hepatic fibrosis can be achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedical nanomaterials, and in particular relates to an ultrasonic explosion nanobubble targeting hepatic stellate cells and a preparation method and application thereof. Background Art

[0002] Liver fibrosis is an abnormal wound repair response caused by a variety of chronic liver injuries, characterized by diffuse extracellular matrix (ECM) excessive deposition and abnormal connective tissue proliferation. Excessive drinking, viral or microbial infection, genetic diseases, autoimmunity and high fat intake can cause liver damage and lead to liver fibrosis. If left untreated, fibrosis may develop into cirrhosis, organ failure, and even more serious hepatocellular carcinoma (HCC). When liver fibrosis progresses to cirrhosis, there is no clinically proven treatment to reverse liver fibrosis except for liver transplantation, but liver transplantation is limited by suitable donors and post-transplant immune response.

[0003] Hepatic stellate cells (HSCs) account for about 10% of all resident hepatocytes. In a normal liver, HSCs maintain a non-proliferative, quiescent phenotype. However, when the liver is damaged, hepatocytes undergo apoptosis or necrosis, followed by the release of pro-inflammatory cytokines and pro-fibrotic cytokines, which stimulate the recruitment and activation of inflammatory cells in the liver. At this time, HSCs are activated and transformed from vitamin A-storing cells to myofibroblasts, and have proliferation, contraction, and chemotaxis functions, thereby producing excessive ECM components, which gather in hepatocytes, destroy the liver structure, and form unique scar tissue. Therefore, the activation and proliferation of HSCs is an important event in liver fibrosis. Activated HSCs express α-smooth muscle actin (α-SMA) and produce pro-fibrotic cytokines such as transforming growth factor (TGF) and platelet-derived growth factor, which lead to excessive production of ECM. Inhibiting the activation of HSCs is the key to promoting the reversal of liver fibrosis. PPARγ agonist treatment can prevent HSC activation, inhibit the proliferation of HSCs and induce apoptosis, and significantly inhibit the expression of TGF-induced connective tissue growth factor (CTGF), thereby improving liver fibrosis. PPARγ selective agonists represented by rosiglitazone (RGZ) are clinically used to lower blood sugar and treat type 2 diabetes. In addition, RGZ has been shown to have anti-liver fibrosis properties. However, the main problem of RGZ in vivo is the lack of specificity for the liver and the short half-life, which means that insufficient drug concentration may not be able to accumulate in target organs and cells. In addition, drug uptake by non-target cells may cause serious side effects, especially when administered for a long time. In recent years, the rapid development of nano drug delivery systems has provided new ideas for the treatment of liver fibrosis. Nano drugs with large capacity, high efficiency, targeted effects, and multi-point regulation are expected to become a treatment for liver fibrosis in the future. How to design and construct a new drug delivery system for liver fibrosis and improve the effect of treating liver fibrosis is a technical problem to be solved by the present invention and a goal to be achieved urgently. Summary of the invention

[0004] In order to overcome the technical problem that existing drugs have poor therapeutic effects on liver fibrosis, the present invention proposes an ultrasonic blasting nanobubble targeting hepatic stellate cells and a preparation method and application thereof based on the biological characteristics of liver fibrosis. The ultrasonic blasting nanobubble targeting hepatic stellate cells has a high degree of targeting to activated HSCs, a high drug utilization rate, low side effects, good biocompatibility, and significantly improves the effect of treating liver fibrosis.

[0005] The present invention provides an ultrasonic explosion nanobubble targeting hepatic stellate cells, wherein the ultrasonic explosion nanobubble comprises:

[0006] (1) Nanovesicles, the nanovesicles comprising a wall material and an anti-liver fibrosis drug and a perfluoroalkane encapsulated in the wall material;

[0007] (2) A hepatic stellate cell targeting polypeptide, which is attached to the surface of the nanovesicle.

[0008] In the present invention, "perfluoroalkane" refers to a perfluoroalkane obtained by replacing all hydrogen atoms connected to carbon atoms in an alkane with fluorine atoms. Specifically, it can be a perfluoroalkane with 1 to 20 carbon atoms, such as but not limited to perfluoropropane, perfluorohexane, perfluoropentane, etc.

[0009] Further, the wall material includes 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol-maleimide (DSPE-PEG-MAL) and / or 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol-carboxyl (DSPE-PEG-COOH); preferably, the wall material also includes cholesterol and / or 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine (DSPE).

[0010] Furthermore, the mass ratio of the wall material to the anti-liver fibrosis drug is 3-120:1-30; preferably 3-6:1; more preferably 4:1.

[0011] Furthermore, the wall material comprises cholesterol, 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol-maleimide and 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine in a mass ratio of 1 to 30: 1 to 80: 1 to 10; preferably, in the wall material, the mass ratio of cholesterol, 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol-maleimide and 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine is 30:70-80:8-10, more preferably 30:80:10.

[0012] Furthermore, the ratio of the mass of the perfluoroalkane to the sum of the mass of the wall material and the anti-liver fibrosis drug is 0.01-1.

[0013] Furthermore, the mass ratio of the nanovesicle to the hepatic stellate cell targeting polypeptide is 50-150 mg: 50-150 μg.

[0014] Further, the anti-liver fibrosis drug is one or more of rosiglitazone, aspirin, melaleuca A, methyl ferulate, tiopronin, silymarin, and sacatinib (RGZ): and / or,

[0015] The perfluoroalkane is perfluoropentane (PFP): and / or,

[0016] The hepatic stellate cell targeting polypeptide is an unmodified RGD peptide or an RGD peptide with modified thiol groups.

[0017] Furthermore, the surface of the nanovesicle also has a maleimide group or a carboxyl group, and the nanovesicle is connected to the RGD peptide modified with a thiol group via the maleimide group or is connected to the unmodified RGD peptide via the amide group formed after the carboxyl group is activated.

[0018] The present invention also provides a method for preparing ultrasonic explosion nanobubbles targeting hepatic stellate cells, comprising the following steps:

[0019] (1) dissolving the wall material and the anti-liver fibrosis drug in an organic solvent, rotary evaporating to obtain a film material, and then drying to obtain the drug-loaded liposomes;

[0020] (2) dispersing the drug-loaded liposomes in an aqueous solution, mixing with perfluoroalkane, and emulsifying to obtain a dispersion containing nanovesicles;

[0021] (3) Mixing the dispersion containing the nanovesicles with the hepatic stellate cell targeting polypeptide to react and prepare ultrasonic explosion nanovesicles.

[0022] Furthermore, in step (1), the organic solvent is selected from one or more of tetrahydrofuran, chloroform, dichloromethane, benzene, toluene, and acetone; and / or the ratio of the sum of the masses of cholesterol, 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol-maleimide, 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine and the anti-liver fibrosis drug to the volume of the organic solvent is 4 to 150 mg: 1 to 30 mL; and / or the rotary evaporation temperature is 40 to 60° C. and the time is 1.5 to 3 hours; and / or, before mixing in step (3), the step of activating the carboxyl group of the dispersion containing the nanovesicles with EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride) / NHS (N-hydroxysuccinimide) is also included.

[0023] Furthermore, in step (1), the hydration is performed by adding an aqueous solution for ultrasonic oscillation. Preferably, the ratio of the sum of the masses of the cholesterol, 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol-maleimide, 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine and the anti-liver fibrosis drug to the volume of the aqueous solution is 4 to 150 mg: 1 to 15 mL; preferably, the aqueous solution is selected from phosphate buffered saline (PBS) or water.

[0024] Furthermore, the ultrasonic oscillation time is 10-60 minutes. Furthermore, the drying is freeze drying. The freeze drying temperature is -30 to -55°C.

[0025] Furthermore, in step (2), the emulsification is ultrasonic emulsification under ice bath conditions, the ultrasonic power of ultrasonic emulsification is 140-160 W, the ultrasonic interval is 2-4 seconds, and the total ultrasonic time is 5-30 minutes.

[0026] Furthermore, in step (2), the volume ratio of the mass of the drug-loaded liposomes to the aqueous solution is 50-300 mg:10 mL; and / or, the aqueous solution is selected from phosphate buffer or water.

[0027] Furthermore, the step (1) includes dialyzing the hydrated product before drying or the step (4) includes dialyzing the reaction solution after reacting; preferably, the dialysis medium is water; preferably, the dialysis time is 24-48 hours.

[0028] Furthermore, in the step of activating the carboxyl group with EDC / NHS, the mass ratio of EDC, NHS and nanovesicles is 3-8:1-5:5-20.

[0029] Furthermore, step (3) is carried out at room temperature for 3-5 hours.

[0030] Furthermore, the mass concentration of the dispersion containing nanovesicles in step (3) is 5-20 mg / mL.

[0031] The present invention also provides the use of any of the above-mentioned ultrasonic explosion nanobubbles targeting hepatic stellate cells or the ultrasonic explosion nanobubbles targeting hepatic stellate cells prepared by any of the above-mentioned preparation methods in the preparation of drugs for preventing or treating liver fibrosis.

[0032] Furthermore, the drug can prevent or treat liver fibrosis under ultrasound mediation.

[0033] Compared with the prior art, the above technical solution of the present invention has the following advantages:

[0034] 1. The ultrasonic blasting nanobubble targeting hepatic stellate cells provided by the present invention comprises a nanovesicle and a hepatic stellate cell targeting polypeptide connected to the surface of the nanovesicle, wherein the nanovesicle comprises a wall material and an anti-hepatic fibrosis drug and a perfluoroalkane coated in the wall material. The perfluoroalkane and the anti-hepatic fibrosis drug are simultaneously loaded therein by the setting of the nanovesicle, and combined with the hepatic stellate cell targeting polypeptide, a novel ultrasonic blasting nanobubble targeting hepatic stellate cells different from the traditional drug delivery system is constructed. The ultrasonic blasting nanobubble can not only actively target and aggregate at the site of liver fibrosis, and has the targeting performance for activating hepatic stellate cells, but also stimulates the perfluoroalkane to undergo phase change under ultrasonic irradiation, locates the blasting carrier, has the ultrasonic response blasting performance, promotes the precise release of the anti-hepatic fibrosis drug at the site of liver fibrosis, and effectively inhibits the activation of HSCs to treat liver fibrosis by increasing the local drug concentration, significantly improves the drug utilization rate, greatly reduces the side effects of the drug on the whole body, and realizes the precise treatment of liver fibrosis.

[0035] 2. The ultrasonic explosion nanobubbles targeting hepatic stellate cells provided by the present invention, wherein the wall material includes 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol-maleimide and / or 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol-carboxyl; preferably, the wall material also includes cholesterol and / or 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine, and the nanovesicles formed by combining cholesterol, 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol-maleimide and 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine as carriers enable the drugs to more efficiently load anti-liver fibrosis drugs and perfluoroalkanes in the nanovesicles, forming stable, high encapsulation rate, high loading amount and uniform particle size distribution ultrasonic explosion nanobubbles, and the ultrasonic explosion nanobubbles have good biocompatibility and biodegradability.

[0036] In summary, the ultrasonic explosion nanobubbles of the present invention include cholesterol, 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol-maleimide, 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine, anti-liver fibrosis drugs and perfluoroalkane, and hepatic stellate cell targeting polypeptides connected to the surface of the nanobubbles. They have high targeting and good biocompatibility to liver fibrosis sites, significantly reduce side effects, improve the therapeutic effect of liver fibrosis, and can achieve precise treatment of liver fibrosis.

[0037] 3. The ultrasonic explosion nanobubbles targeting hepatic stellate cells provided by the present invention can further improve the encapsulation rate, drug loading or particle size distribution uniformity of the ultrasonic explosion nanobubbles by controlling the mass ratio of cholesterol, 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol-maleimide and 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine to 1-30:1-80:1-10, preferably 30:70-80:8-10, and more preferably 30:80:10; or by controlling the mass ratio of the wall material to the anti-liver fibrosis drug to 3-120:1-30; preferably 3-6:1; more preferably 4:1.

[0038] 4. The preparation method of the ultrasonic explosion nanobubble targeting hepatic stellate cells provided by the present invention is to dissolve the wall material and the anti-liver fibrosis drug in an organic solvent by thin film hydration method, obtain the thin film material by rotary evaporation, obtain the synthetic drug-loaded liposome after hydration and drying, obtain the nanovesicle after emulsification with perfluoroalkane, and finally obtain the nanovesicle by reaction with the targeting polypeptide. The preparation process is simple and can be applied to large-scale production. Moreover, the ultrasonic explosion nanobubble prepared by the preparation method has high encapsulation rate, high drug loading and uniform particle size. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] In order to make the content of the present invention more clearly understood, the present invention is further described in detail below according to specific embodiments of the present invention in conjunction with the accompanying drawings, wherein:

[0040] Figure 1 The morphology and particle size distribution diagram of RGZ / PFP@LNP-RGD prepared in Example 1;

[0041] Figure 2 This is the ultrasound response release curve of RGZ / PFP@LNP-RGD measured in Experimental Example 2;

[0042] Figure 3 The results of targeting of RGZ / PFP@LNP-RGD to liver fibrosis sites determined in Experimental Example 3;

[0043] Figure 4 The results of the hydroxyproline (HYP) content in the therapeutic effect of RGZ / PFP@LNP-RGD on liver fibrosis determined in Experimental Example 4;

[0044] Figure 5 The relative expression level of type I collagen α1 (ColⅠα1) mRNA in the therapeutic effect of RGZ / PFP@LNP-RGD on liver fibrosis determined in Experimental Example 4;

[0045] Figure 6The relative expression level of α-smooth muscle actin (α-SMA) mRNA in the therapeutic effect of RGZ / PFP@LNP-RGD on liver fibrosis determined in Experimental Example 4. DETAILED DESCRIPTION

[0046] The technical solution of the present invention will be described clearly and completely below in conjunction with the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0047] Example 1

[0048] This embodiment provides a method for preparing ultrasonic explosion nanobubbles targeting hepatic stellate cells, comprising the following steps:

[0049] (1) Cholesterol (60 mg), DSPE-PEG-MAL (160 mg), DSPE (20 mg) and RGZ (60 mg) were added to a round-bottom flask and dissolved with tetrahydrofuran (20 mL). After the powder was completely dissolved, the organic solvent was removed by evaporation at 40 °C for 2 hours using a vacuum rotary evaporator to obtain a film material. PBS buffer (10 mL, pH 7.4) was added to the film material and ultrasonically vibrated for 20 minutes to obtain a drug-loaded liposome dispersion. The drug-loaded liposome dispersion was then transferred to a dialysis bag, dialyzed with deionized water for 48 hours, and freeze-dried at -45 °C to obtain drug-loaded liposomes, which were recorded as RGZ@LNP.

[0050] (2) 200 mg of RGZ@LNP was dissolved in 10 mL of deionized water and transferred to a 20 mL test tube, and PFP (100 μL) was slowly added. Under ice bath conditions, an ultrasonic crusher (150 W, 5 s interval) was used for emulsification for 20 min (total ultrasonic time 20 min) to prepare nanovesicles (emulsion) loaded with drugs and PFP, which were recorded as RGZ / PFP@LNP and stored at 4 °C.

[0051] (3) Take the RGZ / PFP@LNP prepared in step (2) and dilute it with water to prepare a RGZ / PFP@LNP dispersion with a mass concentration of 10 mg / mL (the mass concentration is equal to the total mass of RGZ@LNP and PFP used in step (2) divided by the volume of the diluted dispersion), take 10 mL of the RGZ / PFP@LNP dispersion with a concentration of 10 mg / mL, add the thiol-modified RGD short peptide (the amino acid sequence of the short peptide is: Cys-Arg-Gly-Asp, 100 μg) at room temperature, and stir for 4 hours to react. After the reaction is completed, the reaction solution is transferred to a dialysis bag (MWCO=3500) and dialyzed with ultrapure water at low temperature (temperature 4°C) for 24 hours to obtain ultrasonic explosion nanobubbles (emulsion) targeting hepatic stellate cells, which is recorded as RGZ / PFP@LNP-RGD emulsion and stored at 4°C.

[0052] The particle size and particle size distribution of RGZ / PFP@LNP-RGD emulsion were characterized by a particle size meter (e.g. Figure 1 The average particle size is 357.44±20.64nm, the PDI is 0.294, and the particle size distribution is narrow.

[0053] Example 2

[0054] This embodiment provides a method for preparing ultrasonic explosion nanobubbles targeting hepatic stellate cells, which is basically the same as Example 1, except that the amounts of DSPE-PEG-MAL and DSPE in step (1) are different and the amount of PFP in step (2) is different; in this embodiment, the amount of DSPE-PEG-MAL is adjusted to 60 mg, the amount of DSPE is adjusted to 60 mg, and the amount of PFP is adjusted to 18 mg.

[0055] Example 3

[0056] This embodiment provides a method for preparing ultrasonic explosion nanobubbles targeting hepatic stellate cells, which is basically the same as that of Example 1, except that the amount of RGZ added in step (1) is adjusted to 40 mg.

[0057] Example 4

[0058] This example provides a method for preparing ultrasonic explosion nanobubbles targeting hepatic stellate cells, which is basically the same as Example 1, except that cholesterol and DSPE are not added in step (1), and the amount of DSPE-PEG-MAL is increased from 160 mg to 240 mg.

[0059] Example 5

[0060] This embodiment provides a method for preparing ultrasonic explosion nanobubbles targeting hepatic stellate cells, which is basically the same as that of Example 1, except that the types of auxiliary materials in step (1) and the operation and reaction conditions of step (3) are different. Specifically, in this embodiment, DSPE-PEG-MAL is replaced with DSPE-PEG-COOH of the same mass in step (1); step (3) of this embodiment is: taking the RGZ / PFP@LNP prepared in step (2) and diluting it with water to prepare RGZ / PFP@LNP with a mass concentration of 10 mg / mL; LNP dispersion, take 10mL of RGZ / PFP@LNP dispersion with a concentration of 10mg / mL, first activate the carboxyl group with EDC / NHS (specifically, 50mgEDC and 25mgNHS are dissolved in 10mL pure water, added dropwise to 10mL RGZ / PFP@LNP dispersion with a concentration of 10mg / mL and stirred at room temperature for 2 hours), add RGD short peptide without thiol modification (the amino acid sequence of the short peptide is: Arg-Gly-Asp, 100μg) at room temperature, and stir for another 2 hours to react. After the reaction is completed, the reaction solution is transferred to a dialysis bag (MWCO=3500), dialyzed with ultrapure water at low temperature (temperature 4°C) for 24 hours, and ultrasonic explosion nanobubbles targeting hepatic stellate cells are obtained, which are recorded as RGZ / PFP@LNP-RGD emulsions and stored in a refrigerator at 4°C.

[0061] Experimental Example 1

[0062] The particle size, drug loading and encapsulation efficiency of the ultrasonic explosion nanobubbles prepared in each embodiment were tested.

[0063] The specific test method of the particle size test is as follows: the particle size distribution of the sample is measured by dynamic light scattering (DLS). In the experiment, the particle size distribution of the RGZ / PFP@LNP-RGD emulsion is measured by a Malvern Zetasizer Nano-ZS 90 particle size analyzer, and the test temperature is 25°C.

[0064] The specific test methods for drug loading and encapsulation efficiency are as follows:

[0065] (1) Preparation of standard solution: Accurately weigh RGZ and dissolve it in methanol to prepare a standard solution of 5-100 μg / ml;

[0066] (2) Preparation of the test solution: Add pure water to the RGZ / PFP@LNP-RGD emulsion to dilute it to a dispersion with a concentration of 1 mg / mL (the concentration of the dispersion is equal to the sum of the mass of the RGZ / PFP@LNP used in step (3) of each example and the mass of the RGD short peptide modified with thiol groups divided by the volume of the diluted dispersion, where the mass of RGZ / PFP@LNP = 10 mg / mL × 10 mL = 100 mg), to obtain the test solution;

[0067] (3) The standard solution and the test solution were detected by HPLC, and the peak area of ​​RGZ in the standard solution was used as the ordinate and the concentration (μg / mL) was used as the abscissa to perform linear regression to obtain the linear regression equation. The peak area ratio of the test solution was substituted into the linear regression equation to calculate the RGZ content of the RGZ / PFP@LNP-RGD emulsion, thereby calculating the mass of the drug in the carrier. Chromatographic conditions: UV200 ultraviolet detector, chromatographic column Ultimate LP-C18 (250×4.6mm, 5μm), mobile phase methanol-0.1% potassium phosphate solution (70:30), detection wavelength 244nm, flow rate 1.0mL / min, column temperature 25C, injection volume 10μL.

[0068] The drug loading and encapsulation efficiency of ultrasonic explosion nanobubbles were calculated according to the following formula. The test was performed three times in parallel, and the average value was taken. The drug loading and encapsulation efficiency results are shown in Table 1 below.

[0069]

[0070] Table 1 Characterization results of ultrasonic explosion nanobubbles in various examples

[0071] project Average particle size PDI Encapsulation efficiency Drug loading Example 1 357.44±20.64nm 0.294 90.05±1.64% 10.15±0.14% Example 2 323.75±15.56nm 0.406 67.23±3.07% 15.32±0.46% Example 3 337.66±12.11nm 0.262 92.83±0.96% 5.9±0.30% Example 4 296.42±21.75nm 0.614 89.47±1.27% 8.5±0.67% Example 5 374±33.22nm 0.368 88.36±2.64% 9.3±0.34%

[0072] The experimental results show that compared with Examples 2-3, Example 1 can ensure uniform dispersion while having a higher drug encapsulation rate and drug loading, and has a higher economic value by limiting the mass ratio of cholesterol, 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol-maleimide, 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine and / or the mass ratio of the wall material to the anti-liver fibrosis drug within the preferred range. Among them, Example 2 has poor dispersibility and a low encapsulation rate, and Example 3 has a low drug loading, and there is still room for drug loading inside the nanobubbles.

[0073] Compared with Example 4-5, Example 1 uses cholesterol, 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol-maleimide, 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine to construct wall materials and simultaneously encapsulate anti-liver fibrosis drugs and perfluoroalkane, which can obtain higher drug loading and encapsulation efficiency on the basis of reducing PDI. The PDI of Examples 4 and 5 becomes larger, indicating that the dispersion of the nanobubble solution is not good. In addition, Example 1 uses Michael addition reaction to directly modify RGD short peptide at room temperature, and the method is simple, while Example 5 needs to be activated by EDC / NHS and then coupled with RGD short peptide, and the reaction is more complicated, and the large-scale production is not as simple as Example 1.

[0074] Experimental Example 2 Ultrasonic response release behavior of ultrasonically exploded nanobubbles targeting hepatic stellate cells

[0075] The RGZ / PFP@LNP-RGD emulsion prepared in Example 1 was prepared into a dispersion with a concentration of 2 mg / mL using water as a solvent (the concentration of the dispersion is equal to the sum of the mass of the RGZ / PFP@LNP used in step (3) of Example 1 and the mass of the RGD short peptide modified with a thiol group divided by the volume of the diluted dispersion, where the mass of RGZ / PFP@LNP = 10 mg / mL × 10 mL = 100 mg), which may also be referred to as the mother solution below), and then added to dialysis bags (MW is 3500Da, 3 parallel samples per group, 2 groups in total), and 10 mL of the mother solution was added to each dialysis bag. The sealed dialysis bags were immersed in 50 mL of PBS (pH 7.4) and shaken at 100 rpm at 37°C.

[0076] In one group, samples were treated with ultrasound (US) for 60 s using an SP100 sonicator with a frequency of 1 MHz and a duty cycle of 50% 6 h after sampling (i.e., the RGZ / PFP@LNP-RGD+ultrasound intervention group), while the other group did not receive US treatment (i.e., the RGZ / PFP@LNP-RGD group).

[0077] For the above two groups, 1 mL of the solution in the dialysis bag was taken at 0, 2, 6, 12, 24, 48, and 72 h, and an equal volume of PBS was added to the solution. The samples were taken out and analyzed by HPLC injection. The concentration of RGZ in the sample solution at each time point was calculated using the standard curve, and the cumulative release of RGZ was calculated to draw the release curve. The cumulative release was calculated according to the following formula:

[0078]

[0079] C n : the concentration of the solution in the dialysis bag at the nth hour, V: the volume of the solution in the dialysis bag (10 mL), C k-1 : The concentration of the solution in the dialysis bag at hour n-1, V x : Volume of solution collected at each time point (1 mL), C: concentration of mother solution (2 mg / mL).

[0080] like Figure 2As shown, in the RGZ / PFP@LNP-RGD group without ultrasound intervention, RGZ / PFP@LNP-RGD released 19.61% of RGZ in the first 6 hours, and then released 28.91% of RGZ very slowly within 72 hours. In the RGZ / PFP@LNP-RGD+ultrasound intervention group experiment, there was no ultrasound intervention within 6 hours, and the cumulative release of RGZ was 18.44%. After 6 hours of sampling, ultrasound intervention was added, and the cumulative release of RGZ reached 78.81% within 72 hours. It shows that the release amount and efficiency of RGZ in RGZ / PFP@LNP-RGD can be quickly improved under the intervention of ultrasound. This suggests that the RGZ / PFP@LNP-RGD emulsion of the present invention has the ability of ultrasound response release.

[0081] Experimental Example 3 In vivo distribution of ultrasound-detonated nanobubbles targeting hepatic stellate cells

[0082] 1. Experimental methods

[0083] Preparation method of Cy5.5-labeled nanobubbles: Ultrasonic explosion nanobubbles targeting hepatic stellate cells were prepared basically according to the method of Example 1, and the only difference from Example 1 was that the same mass of Cy5.5 was used instead of RGZ in step (1), and the rest of the process and conditions were the same as those in Example 1, and finally Cy5.5-labeled nanobubbles were prepared, which were recorded as Cy5.5 / PFP@LNP-RGD emulsion. Water was used as the solvent to prepare a Cy5.5-labeled nanobubble dispersion with a concentration of 5 mg / mL, and the concentration calculation method was the same as that in Experimental Example 2.

[0084] A rat model of liver fibrosis was established using carbon tetrachloride (CCl4) in 4-week-old male SD rats. The rats were given standard pelleted feed and water, and CCl4 modeling agent was injected intraperitoneally twice a week (the injection dosage was determined according to the rat body weight: 1 mL of CCl4 modeling agent was injected per kg of rat body weight, and the modeling agent was a uniform mixture of CCl4 and olive oil in a volume ratio of 1:1) for 10 consecutive weeks.

[0085] After the model was successfully constructed, 5 mg / mL of Cy5.5-labeled nanobubble dispersion was injected into rats via tail vein injection. The injection volume for each rat was 200uL. The in vivo distribution of nanobubbles was detected by the small animal in vivo imaging system 1h, 6h, 12h, and 24h after injection.

[0086] 2. Experimental results

[0087] The results are as follows Figure 3As shown in the figure, the fluorescence intensity of the heart, liver, spleen, lung and kidney organs in the rat body was statistically analyzed, and it was found that the relative fluorescence intensity of the liver was significantly higher than that of other parts (p<0.05), indicating that the nanobubbles of the present invention have obvious targeting to the liver. The relative fluorescence intensity of the liver part at 6h and 24h was 10.33 and 4.36 respectively, and the relative fluorescence intensity of other parts was lower than that of the liver part.

[0088] Experimental Example 4 Therapeutic effect of ultrasonic explosion nanobubbles targeting hepatic stellate cells on liver fibrosis

[0089] 1. Experimental methods

[0090] The RGZ / PFP@LNP-RGD emulsion prepared in Example 1 was prepared into a dispersion with a concentration of 5 mg / mL using water as a solvent. The concentration calculation method was the same as that in Experimental Example 2.

[0091] Fifteen 4-week-old SD rats were selected and randomly divided into three groups: normal group, liver fibrosis + normal saline group, and liver fibrosis + RGZ / PFP@LNP-RGD group, with 5 rats in each group.

[0092] In addition to the normal group, rats in the liver fibrosis + saline group and the liver fibrosis + RGZ / PFP@LNP-RGD group were treated with carbon tetrachloride to construct a liver fibrosis rat model. The rats were given standard pellet feed and water, and CCl4 modeling agent was injected intraperitoneally twice a week (the injection amount was determined according to the rat body weight: 1 mL of CCl4 modeling agent was injected per kg of rat body weight, and the modeling agent was a 1:1 mixture of CCl4 and olive oil), for 10 consecutive weeks to construct a liver fibrosis model. Rats in the normal group were given standard pellet feed and water.

[0093] After the model was successfully constructed, for the liver fibrosis + RGZ / PFP@LNP-RGD group, 5 mg / mL of RGZ / PFP@LNP-RGD dispersion was intravenously injected once every 3 days. The injection dosage was determined according to the weight of the rats. Each dose was 30 mg / kg of RGZ. One hour after the injection, ultrasound was applied to the liver of the rats for 60 seconds (SP100 sonicator with a frequency of 1 MHz and a duty cycle of 50%). The treatment period was 6 weeks. The normal group and the liver fibrosis + saline group were injected with an equal volume of saline at the same time.

[0094] At the end of the treatment period, the rat livers were collected and the content of liver fibrosis marker hydroxyproline (HYP) in the liver tissue was detected using a kit (catalog number ab222941) according to the method described in the kit instructions. PCR was used to detect the relative expression levels of type I collagen α1 (ColⅠα1) and α-smooth muscle actin (α-SMA) mRNA in the liver tissue.

[0095] 2. Experimental results

[0096] Figure 4-6 The results showed that compared with the normal group, the levels of three liver fibrosis markers in the liver fibrosis + saline group were significantly increased (p<0.05). Compared with the liver fibrosis + saline group, the levels of liver fibrosis markers in the RGZ / PFP@LNP-RGD ultrasound treatment group (liver fibrosis + RGZ / PFP@LNP-RGD group) were significantly decreased (p<0.05), indicating that RGZ / PFP@LNP-RGD can effectively inhibit the development of liver fibrosis under ultrasound mediation.

[0097] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the scope of protection of the invention.

Claims

1. An ultrasonic explosion nanobubble targeting hepatic stellate cells, characterized in that: The ultrasonic explosion nanobubbles targeting hepatic stellate cells include: (1) Nanovesicles, wherein the nanovesicles include a wall material and an anti-liver fibrosis drug and a perfluoroalkane encapsulated in the wall material; (2) A hepatic stellate cell targeting polypeptide, which is attached to the surface of the nanovesicle.

2. The ultrasonic explosion nanobubble targeting hepatic stellate cells according to claim 1, characterized in that: The wall material includes 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol-maleimide and / or 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol-carboxyl; preferably, the wall material also includes cholesterol and / or 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine.

3. The ultrasonic explosion nanobubble targeting hepatic stellate cells according to claim 1 or 2, characterized in that: The mass ratio of the wall material to the anti-liver fibrosis drug is 3-120:1-30; preferably 3-6:1; more preferably 4:

1.

4. The ultrasonic explosion nanobubble targeting hepatic stellate cells according to any one of claims 1 to 3, characterized in that: The wall material includes cholesterol, 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol-maleimide and 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine in a mass ratio of 1 to 30:1 to 80:1 to 10; preferably, in the wall material, the mass ratio of cholesterol, 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol-maleimide and 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine is 30:70-80:8-10, more preferably 30:80:

10.

5. The ultrasonic explosion nanobubble targeting hepatic stellate cells according to any one of claims 1 to 4, characterized in that: The ratio of the mass of the perfluoroalkane to the sum of the mass of the wall material and the anti-liver fibrosis drug is 0.01-1.

6. The ultrasonic explosion nanobubble targeting hepatic stellate cells according to any one of claims 1 to 5, characterized in that: The anti-liver fibrosis drug is one or more of rosiglitazone, aspirin, melaleuca A, methyl ferulate, tiopronin, silymarin, and salactinib: and / or, The perfluoroalkane is perfluoropentane: and / or, The hepatic stellate cell targeting polypeptide is an unmodified RGD peptide or a thiol-modified RGD peptide.

7. A method for preparing ultrasonic explosion nanobubbles targeting hepatic stellate cells, characterized in that: The steps include: (1) dissolving the wall material and the anti-liver fibrosis drug in an organic solvent, rotary evaporating to obtain a film material, and then hydrating and drying to obtain the drug-loaded liposomes; (2) dispersing the drug-loaded liposomes in an aqueous solution, mixing with perfluoroalkane, and emulsifying to obtain a dispersion containing nanovesicles; (3) Mixing the dispersion containing the nanovesicles with the hepatic stellate cell targeting polypeptide to react and prepare ultrasonic explosion nanovesicles.

8. The method for preparing ultrasonic explosion nanobubbles targeting hepatic stellate cells according to claim 7, characterized in that: In step (1), the organic solvent is selected from one or more of tetrahydrofuran, chloroform, dichloromethane, benzene, toluene, and acetone; and / or the ratio of the sum of the mass of the wall material and the anti-liver fibrosis drug to the volume of the organic solvent is 4-150 mg: 1-30 mL; and / or the temperature of the rotary evaporation is 40-60° C. and the time is 1.5-3 hours; and / or, before mixing in step (3), the step of activating the carboxyl group of the dispersion containing the nanovesicles with EDC / NHS is also included.

9. The method for preparing ultrasonic explosion nanobubbles targeting hepatic stellate cells according to claim 7 or 8, characterized in that: In step (1), the hydration is performed by adding an aqueous solution for ultrasonic oscillation. Preferably, the ratio of the sum of the masses of the wall material and the anti-liver fibrosis drug to the volume of the aqueous solution is 4-150 mg: 1-15 mL; preferably, the aqueous solution is selected from phosphate buffer or water.

10. Use of the ultrasonic explosion nanobubble targeting hepatic stellate cells as claimed in any one of claims 1 to 6 or the ultrasonic explosion nanobubble targeting hepatic stellate cells prepared by the preparation method as claimed in any one of claims 7 to 9 in preparing a drug for preventing or treating liver fibrosis.

Citation Information

Patent Citations

  • Ultrasonic sensitive medicament-carried nanometer bubble

    CN101683272A

  • Targeted drug-bearing ultrasonic microbubble and preparation method thereof

    CN102138889A

  • Small interfering ribonucleic acid (siRNA) lipid nanometer vesicles with targeted hepatic stellate cells, and application of siRNA lipid nanometer vesicles

    CN105688229A

  • Nano-ultrasonic microbubble, as well as preparation method and application thereof

    CN111298142A

  • Hydrocortisone multifunctional ultrasonic microbubble with targeting function for treating cerebral apoplexy

    CN115154472A